


Our special edition focuses on those new, mainly innovative pharmaceutical technologies, which were admitted to the reimbursement system on 1st of January 2022. In case of these submissions NHIFA¹ cannot decide on its own competence. The analysis was based on the information contained in the list of reimbursement submissions, regularly published by NHIFA.*


After the change of legislation in 2018, the analysis of a submission's timeline faces many obstacles, since these procedures have to be closed within 360 days. In the case of submissions that appear to exceed this procedure time, companies tend to initiate the closure of the process and resubmitting the dossiers without any, or with minimal changes. In our analysis, the requests closed by a termination order and submitted again within a few

* In this analysis we have used the information that was published on 24th of February, 2022 by NHIFA


Submissions by type of legislation amendment




Number of submissions




Average procedure length by reimbursement category (days)




Average of days passed from submission to admission by companies (brands)




Top 4 applicants by the number of brands and applications (brands/applications)



Top 3 ATC main group by the number of brands and TTTs (brands/TTTs)



Number of TÉB³ sessions by brands



Actual timelines of ongoing procedures are the following:

- ◆ Average time between (atb) submission and proposal to the TÉF⁴ is 12 days (min. 3 days, max. 23)
- ◆ Atb. the handover to TÉF and the first TÉB session takes 99 days (min. 42, max. 422)
- ◆ Atb. first and last TÉB session is 102 days (min. 14, max. 154)
- ◆ Atb. last TÉB session and proposal to MoH is 159 days (min.19, max. 408)

NHIFA proposes legislation amendment requests intermittently to the Minister responsible for Health Insurance - in line with the TÉB decision -, based on 2006. Act XCVIII. (Gyftv.), according to which reimbursement of pharmaceutical applications or alteration of reimbursement conditions of an already reimbursed medicine requires amendment of legislation.

Transparent traceability of submissions of pharmaceuticals lasts from the moment of submission till the NHIFA proposal to the Ministry. Thereafter, public information is not available regarding the decisions until the publication of the bulletin.

With further questions, please [contact us!](#)

